Activating mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are present in non-squamous non-small cell lung cancer (NSCLC), ranging from 10%–15% in Caucasian to 40%–50% in Asian populations [1–5]. This evidence concerns the gene EGFR and non-small cell squamous lung carcinoma.